RECRUITING

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.

Official Title

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Quick Facts

Study Start:2025-04-01

Study Completion:2028-03-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04383808

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Whole body radiation dose within the last year of less than 5000 mrem 2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved 3. Subjects will be at least 21 years of age 4. Subject provides written informed consent 5. Subject is deemed healthy by the PI by via self-reported questionnaire	1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents 2. Participant has a history of or current diagnosis of cancer 3. Participant is pregnant or nursing 4. Metallic implants (contraindicated for MRI)

Inclusion Criteria

Exclusion Criteria

1. Whole body radiation dose within the last year of less than 5000 mrem
2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
3. Subjects will be at least 21 years of age
4. Subject provides written informed consent
5. Subject is deemed healthy by the PI by via self-reported questionnaire

1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents
2. Participant has a history of or current diagnosis of cancer
3. Participant is pregnant or nursing
4. Metallic implants (contraindicated for MRI)

Contacts and Locations

Study Contact

Paul Newswanger

CONTACT

(650) 736-1349

pdn@stanford.edu

Study Locations (Sites)

Stanford University

Palo Alto, California, 94305

United States

Collaborators and Investigators

Sponsor: Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-01

Study Completion Date2028-03-31

Study Record Updates

Study Start Date2025-04-01

Study Completion Date2028-03-31

Terms related to this study

Additional Relevant MeSH Terms

Brain Disease